UK – 27 June, 2012 – CSL Behring UK Ltd today announce the launch of the Beriplex P/N Dosing Calculator App at The General Anaesthetists in Training Annual Scientific Meeting, taking place in Glasgow. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Beriplex P/N (human prothrombin complex concentrate).
The mobile app, available on both iPhone and Android™ handsets, will calculate the correct dose and volume of Beriplex P/N to be infused based upon entry of only two key pieces of information: the patient’s weight and their initial INR. Users then simply tap calculate to obtain the dose required. This is important for healthcare professionals in cases where information is needed quickly in order to make effective, timely decisions, such as in an emergency setting.
Research indicates a high level of smart phone usage amongst healthcare professionals in the UK. 82% of healthcare professionals own a smart phone and 88% use them to communicate with other colleagues at work1. 59% use their device for accessing information on the internet or intranet and 30% use work related software apps1. The new Beriplex P/N Dosing Calculator App supports this growing trend by providing fast, accurate, and easy to obtain dosage information to healthcare professionals when time is of the essence.
Commenting on the new app Eddie Owens, General Manager, CSL Behring UK Ltd said: “We see that healthcare professionals are clearly using mobile technology to access health information and for us to engage with this growing target audience, we need to be present in this medium. The new Beriplex P/N Dosing Calculator App aims to meet the demand that healthcare professionals have to access sound medical data from anywhere and at anytime.”
Healthcare professionals have several ways to download and install the new Beriplex P/N Dosing Calculator App for free onto their device:
– Directly from the phone – Going online to the iTunes™ store at: http://itunes.apple.com/gb/app/beriplex-dosing-calculator/id486787181?mt=8&ign-mpt=uo%3D4
– Visiting Google Play at: https://play.google.com/store/apps/details?id=com.nitrogen.beriplexdose#?t=W251bGwsMSwxLDIxMiwiY29tLm5pdHJvZ2VuLmJlcmlwbGV4ZG9zZSJd
CSL Behring is a global leader in the plasma protein therapeutics industry. Passionate about improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant products and related services. CSL Behring therapies are used in the treatment of rare diseases such as immune deficiency disorders, hereditary angioedema, haemophilia, von Willebrand disease and other bleeding disorders. Other products are used for the prevention of haemolytic diseases in the newborn. The company also operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.co.uk
For further information please contact:
Joanna Tubbs
Account Manager, Healthcare
Munro & Forster
Tel: 020 7815 3903
Email:Joanna.Tubbs@munroforster.com
Becky Turner
Communications & E-business Executive
CSL Behring UK Ltd
Tel: 01444 447 429
Email:Rebecca.Turner@cslbehring.com
Images of the new Beriplex P/N Dosing Calculator App are available upon request.
Notes to editors
About Beriplex P/N (human prothrombin complex concentrate)
Beriplex P/N is indicated for:
• Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
• Treatment and perioperative prophylaxis of bleedings in congenital deficiency of any of the vitamin K dependent coagulation factors when purified specific coagulation factor products are not available.
Beriplex P/N is a registered trademark of CSL Behring.